Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shibuya

Showing results (461-470 of 463) with videos related to

Pageof 47
Sort By:
You have reached the last page of results.This site can display upto 463 results.
The Review of Scientific Instruments|March 3, 2012
Spatial distribution of the charged particles and potentials during beam extraction in a negative-ion sourceK Tsumori, H Nakano, M Kisaki, et al.
Journal of Medicinal Chemistry|April 18, 2020
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor ActivityPaul R Leger, Dennis X Hu, Berenger Biannic, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Pageof 47

Showing results (461-470 of 463) with videos related to

Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 463 results.
The Review of Scientific Instruments|March 3, 2012
Spatial distribution of the charged particles and potentials during beam extraction in a negative-ion sourceK Tsumori, H Nakano, M Kisaki, et al.
Journal of Medicinal Chemistry|April 18, 2020
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor ActivityPaul R Leger, Dennis X Hu, Berenger Biannic, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Pageof 47